长期高剂量质子泵抑制剂暴露增加系统性硬化症钙质沉着风险
基于单中心两个系统性硬化症队列(199例回顾性队列和215例前瞻性队列),分析质子泵抑制剂(PPI)使用与钙质沉着存在及严重程度的关系。回顾性队列显示高剂量PPI组钙质沉着比例为39%,标准剂量组为20%(P=0.003);前瞻性队列证实PPI暴露时间越长,钙质沉着风险越高,暴露超过10年者风险增加超过6倍(OR 6.37,95%CI 1.92-21.17,P=0.003)。
要点
- 高剂量PPI与系统性硬化症钙质沉着患病率升高相关(39% vs 20%,P=0.003)。
- PPI暴露时间每增加单位,钙质沉着风险增加(OR 1.04,95%CI 1.02-1.06)。
- PPI暴露超过10年者钙质沉着风险较未暴露者增加超过6倍(OR 6.37)。
核心结论
- 高PPI暴露与系统性硬化症钙质沉着的严重程度存在显著关联,PPI暴露可能是可干预的钙质沉着风险因素,需进一步评估。
研究设计与样本
- 单中心两个系统性硬化症队列分析:队列1为199例回顾性数据(10年回顾),队列2为215例前瞻性连续入组患者并接受临床评估。
主要发现
- 队列1中标准剂量PPI组钙质沉着比例为20%,高剂量PPI组为39%(P=0.003)。
- 队列2中钙质沉着(任何时间)风险随PPI暴露时间延长而增加(OR 1.04,95%CI 1.02-1.06,P<0.001),随疾病病程延长而增加(OR 1.08,95%CI 1.05-1.12,P<0.001),随年龄增加而增加(OR 1.03,95%CI 1.01-1.05,P=0.010)。
- 多变量logistic回归调整疾病病程和抗体后,PPI暴露超过10年者钙质沉着风险较无PPI暴露者增加超过6倍(OR 6.37,95%CI 1.92-21.17,P=0.003)。
关键数值与推荐
- 钙质沉着结局定义为当前存在钙质沉着(CC)或任何时间出现钙质沉着(CAT)。
- 队列1高剂量PPI组钙质沉着比例39%,标准剂量组20%(P=0.003)。
- 队列2中PPI暴露>10年对比无PPI暴露的OR为6.37(95%CI 1.92-21.17,P=0.003)。
临床怎么用
- 对系统性硬化症患者应关注PPI暴露时长与剂量,高暴露者需警惕钙质沉着风险。
- PPI暴露作为潜在可干预因素,在管理反流症状时需权衡长期高剂量使用的风险。
局限性
- 研究为单中心设计,样本量有限(队列1 199例,队列2 215例),结论需多中心验证。
- 原文未报告混杂因素完全控制情况,PPI暴露与钙质沉着的因果关系尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association between proton pump inhibitor (PPI) use and the presence and severity of calcinosis in SSc. METHODS: We analysed data from two SSc cohorts from a single centre. Cohort 1 included 199 patients reviewed over 10 years, for whom retrospective data on PPI use and calcinosis were available. Cohort 2 was recruited prospectively and included 215 consecutive patients, who underwent clinical assessment. Outcomes of interest were presence of current calcinosis (CC) or calcinosis at any time (CAT). RESULTS: The cohort 1 data analysis showed that among patients on standard dose PPI 20% had calcinosis, while in those on high doses of PPI calcinosis was present in 39% (P = 0.003). Analysis of the data from cohort 2 confirmed these findings, demonstrating that the odds of CAT increased significantly with longer PPI exposure [odds ratio (OR) 1.04, 95% CI: 1.02, 1.06; P < 0.001], longer disease duration (OR 1.08, 95% CI: 1.05, 1.12; P < 0.001) and greater age (OR 1.03, CI: 1.01, 1.05; P = 0.010). Multivariable logistic regression showed that higher exposure to PPI remained a significant predictor of calcinosis, with PPI exposure >10 years increasing the risk of CAT >6-fold, compared with no PPI (OR 6.37, 95% CI: 1.92, 21.17; P = 0.003) after adjusting for disease duration and antibodies. CONCLUSION: We confirm a significant association between high PPI exposure with severity of calcinosis in SSc. Given the clinical impact of calcinosis and reflux in SSc, PPI exposure as a potentially modifiable risk factor for calcinosis requires further evaluation.
引用
- Host LV, Campochiaro C, Afonso A, et al. High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. Rheumatology (Oxford). 2021. PMID: 32829395. doi:10.1093/rheumatology/keaa332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。